COMP <GO>
XERS vs ABBV // GROSS PROFIT MARGIN
Xeris Biopharma Holdings Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: XERS 1
— ABBV 9
■ METRIC PARITY
LAST: $10.75 (+1.03%) • MKT CAP: $1.96B
gross-margins
—
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XERS VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XERS | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.00% | 29.00% | -13.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 83.1x | 33.3x | +49.80 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 1.46% | 3.47% | -2.01 | ABBV | /fcf-yield <GO> |
| Operating Margin | 8.50% | 24.60% | -16.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 0.20% | 6.90% | -6.70 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 43.70% | 8.60% | +35.10 | XERS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.11 | 5.33 | -3.22 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.0 | 65.1 | -5.08 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.96B | $513.86B | -$511.90B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XERS REV | ABBV REV | XERS GROSS % | ABBV GROSS % | XERS FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $291.8M | $61.16B | — | 70.2% | $28.6M | $17.82B |
| FY 2024 | $203.1M | $56.33B | — | 70.0% | -$37.0M | $17.83B |
| FY 2023 | $163.9M | $54.32B | — | — | -$47.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XERS // BETA —
ABBV // BETA 1.15